CD5 labeling of thymic carcinomas and other nonlymphoid neoplasms.
We studied 109 thymic tumors and 423 other neoplasms for immunocytochemical expression of CD5 in paraffin-embedded tissue using 2 monoclonal antibodies. One of the antibodies (clone CD5/54/B4) labeled 7 (29%) of 24 thymic carcinomas but did not stain any of the other neoplasms. In contrast, the other antibody (clone 4C7) labeled 15 (62%) of 24 thymic carcinomas, 2 (2%) of 84 thymomas, 3 (8%) of 37 lymphomas, and 14 (4%) of 386 other tumors. Among the lymphomas, 4C7 labeled 2 of 4 peripheral T-cell lymphomas and 1 of 4 anaplastic large cell lymphomas. Clone 4C7 produced strong labeling of reactive T lymphocytes, whereas CD5/54/B4 staining of these cells was weak or absent. No other normal cells seemed to stain with either antibody. In conclusion, one CD5 antibody clone (CD5/54/B4) specifically identified 30% of thymic carcinomas. The other CD5 antibody (clone 4C7) identified 62% of thymic carcinomas but also labeled occasional other neoplasms.
Kornstein
M J
MJ
Medical College of Virginia/Virginia Commonwealth University, Richmond 23298-0662, USA.
Rosai
J
J
D000911:Antibodies, Monoclonal; D018956:CD5 Antigens / Q000032:analysis*; D002462:Cell Membrane / Q000276:immunology; D003593:Cytoplasm / Q000276:immunology; D004847:Epithelial Cells / Q000276:immunology; D006801:Humans; D007124:Immunoenzyme Techniques; D008223:Lymphoma / Q000276:immunology; D010232:Paraffin; D013945:Thymoma / Q000276:immunology*; D013953:Thymus Neoplasms / Q000276:immunology*; D016610:Tissue Embedding
D000911:Antibodies, Monoclonal; D018956:CD5 Antigens; D010232:Paraffin